# Diabetes Research Hub — Monitor Report
**Run date:** 2026-05-12
**Run mode:** Automated scheduled review
**Previous report:** monitor_report_2026-05-11.md
**Validation level (per Research Doctrine):** BRONZE for new claims; SILVER for snapshot diffs (reproducible from JSON)

---

## 1. File System Status

| File | Last Modified | Age | Status |
|------|---------------|-----|--------|
| Analysis/Results/hub_monitor_report.md | 2026-05-12 07:05 | 0d | Fresh |
| Analysis/Results/clinical_trials_latest.json | 2026-05-12 07:04 | 0d | Fresh |
| Analysis/Results/pubmed_recent_latest.json | 2026-05-12 07:05 | 0d | Fresh |
| Analysis/Results/literature_gap_report.md | 2026-05-11 08:07 | 1d | Fresh (regenerated) |
| Analysis/Results/literature_gap_data.json | 2026-04-20 15:35 | **22d** | **Stale — underlying counts are from 2026-04-20** |
| Research_Findings_Summary.md | 2026-05-11 08:07 | 1d | Fresh |

The hub_monitor scan reports 557 result files older than 14 days. The most actionable staleness is `literature_gap_data.json` (22 days). The gap report markdown has been regenerated, but the PubMed counts inside it still reflect the April 20 query. **Recommendation:** rerun `python project1_literature_gap_analysis.py` before citing any gap scores externally.

---

## 2. Clinical Trial Changes (2026-05-11 → 2026-05-12)

Source: ClinicalTrials.gov API v2, snapshot of 786 active trials across 5 categories (T1D Cure & Cell Therapy 150, T1D Immunotherapy 71, T2D Novel Therapies 139, Diabetes Tech 221, Recently Completed w/ Results 276).

Net delta: +1 / −1 trial; 1 status change; 0 newly posted results.

| Change | NCT | Title (truncated) | Detail |
|--------|-----|-------------------|--------|
| New | NCT05514535 | Semaglutide + lower-dose insulin glargine vs. higher-dose glargine | Novo Nordisk, Phase 3, status COMPLETED (entered our tracked set as a completed trial) |
| Removed | NCT07212179 | Self-Learning Bolus Calculator With Simplified Meal Announcement in Adolescents With T1D | Was RECRUITING; check whether withdrawn or re-classified |
| Status | NCT07059377 | Semaglutide for Smoking Cessation in Patients With Diabetes | NOT_YET_RECRUITING → RECRUITING |

### Key Phase 3 trials worth watching (still RECRUITING, from priority sponsors)

| NCT | Sponsor | Therapy | Indication |
|-----|---------|---------|------------|
| NCT06832410 | Vertex | VX-880 (zimislecel) | T1D (Phase 3) |
| NCT04786262 | Vertex | VX-880 (zimislecel) | T1D (Phase 3) |
| NCT07222137 | Eli Lilly | Baricitinib (LY3009104) | Delay of Stage 3 T1D in at-risk children (Phase 3) |
| NCT07222332 | Eli Lilly | Baricitinib (LY3009104) | Beta cell preservation in new-onset T1D (Phase 3) |
| NCT07088068 | Sanofi | Teplizumab | T1D (Phase 3 — note: Sanofi now sponsoring after the 2025 Provention/Sanofi T1D pipeline integration) |
| NCT07076199 | Novo Nordisk | Insulin Icodec | Weekly basal insulin (Phase 3) |
| NCT06739122 | Eli Lilly | Dulaglutide (3.0/4.5 mg) | Pediatric T2D (Phase 3) |
| NCT06951074 | Ain Shams U. | iPSC-derived islet transplantation | T1D (Phase 2/3) |

### Recently posted results (since 2026-03-12) worth reviewing

Highest priority for our literature pipeline:
- **NCT05971940** — Orforglipron (LY3502970) in T2D, Phase 3 — results posted 2026-04-22. Pair with the new pharmacokinetic bioequivalence paper (PMID 41994902, captured in last 30 days).
- **NCT05144984** — Semaglutide + NNC0480-0389 combination in T2D — results posted 2026-04-09 (Novo Nordisk pipeline).
- **NCT05649137** — Semaglutide for excess weight + T2D — results posted 2026-04-27.
- **NCT05238142** — MiniMed 780G AHCL in T2D — results posted 2026-04-16 (Closed Loop AP domain).
- **NCT05923827** — Omnipod 5 + Libre 2 vs. MDI in T1D — results posted 2026-04-14.
- **NCT04557228** — ADAM17 and vascular function in diabetes — results posted 2026-05-04 (relevant to Multi-Omics Biomarker Integration, Tier 1 area).

Total trials with newly-posted results in the last 60 days: 33. Full list in `clinical_trials_latest.json` (filter `results_posted >= 2026-03-12`).

---

## 3. PubMed Highlights (last 30 days, 144 unique papers)

19 new papers entered the snapshot today; 16 dropped out (rolling 30-day window).

### Cross-domain papers (appear in ≥2 alert domains — highest signal)

| PMID | Title | Domains |
|------|-------|---------|
| 42114520 | Tirzepatide vs. dulaglutide: major kidney events in T2D (pre-specified analysis) | T2D GLP-1 New + Diabetes Gene Therapy |
| 42109093 | TECPR2 case solved through multi-omic genomics | Diabetes Biomarker + Diabetes Multi-Omics |
| 42104727 | Stem cell-based therapies for T1D: progress in differentiation & clinical translation | T1D Stem Cell Cure + Diabetes Gene Therapy |
| 42108331 | Automated insulin delivery in diabetes + advanced [kidney disease] | T2D GLP-1 New + T2D Remission + Closed Loop AP |
| 42103860 | Ubiquitination-driven fibroblast dysfunction: multi-omics blueprint | Diabetes AI/ML + Diabetes Multi-Omics |
| 42101353 | Causal effects of CRP on disease (multivariable MR) | T2D Remission + Diabetes Biomarker |
| 42099240 | NLRP3 inflammasome mechanisms & therapeutic targets in diabetic [complications] | Diabetes Gene Therapy + Diabetes Complications New |
| 42089665 | VEGFA-targeted M3-F4 LNPs for diabetic retinopathy | Diabetes Gene Therapy + Diabetes Complications New |
| 42051156 | Teplizumab clinical-use consensus statement (Stage 2 T1D) | T1D Immunotherapy + Key Therapy: teplizumab |
| 42101085 | Personalized medicine in ASD: epigenomics, microbiome, multi-omics | Diabetes Microbiome + Diabetes Multi-Omics |
| 42046753 | Breaking up sitting on glucose & vascular function | T1D Immunotherapy + Closed Loop AP |

### Papers mentioning tracked therapies

- **teplizumab** (3): consensus statement (42051156), real-world Stage 2 feasibility (41796109), real-world metabolic/immune evaluation (41535597) — meaningful cluster; consensus statement likely the most citable.
- **orforglipron** (2): bioequivalence of tablet vs. capsule (41994902) and a methodology critique (41984238).
- **retatrutide** (1, new today): triple hormone receptor agonism in CKM syndrome (42108533).
- **baricitinib** (1): off-target dermatology case report only — no diabetes-specific paper this cycle.
- **dapagliflozin** (5 new): pediatric cardiac (42108523), SGLT2 + renal outcome systematic review (42109728), dapa + valsartan cardiorenal (42109733), and others — strong recent volume.
- **zimislecel** (0), **CagriSema** (0): no new PubMed-indexed papers in the window despite active trials.

### Publication volume trends (last 30 days, per alert domain)

Most alert domains hit the per-query cap of 10 papers, which means activity is healthy and the cap is biting. Three domains came in below cap and are genuinely quieter:
- **LADA New Research**: 5
- **Diabetes Drug Repurpose**: 4
- **GLP-1 Pharmacogenomics**: 1

These low-volume domains also overlap with our Tier-1 contribution areas — see §4.

---

## 4. Gap Analysis Summary

Underlying `literature_gap_data.json` is from **2026-04-20** (22 days old). Counts below should be treated as preliminary until the script is rerun.

### Top 5 under-researched intersections (highest gap scores)

| Rank | Domain pair | Joint pubs | Gap score | Rationale (from gap report) |
|------|-------------|------------|-----------|------------------------------|
| 1 | Beta Cell Regen × Health Equity | 0 | 100.0 | No equity analysis of emerging cell therapies |
| 2 | Insulin Resistance × Islet Transplant | 1 | 100.0 | IR in transplant recipients affects graft survival, barely studied |
| 3 | Islet Transplant × Drug Repurposing | 0 | 100.0 | No computational screening of existing immunosuppressants for islet protection |
| 4 | Islet Transplant × Health Equity | 0 | 100.0 | Islet transplant only at select centers; access equity absent |
| 5 | Gene Therapy × LADA | 0 | 100.0 | LADA's autoimmune mechanism is candidate for gene therapy; no crossover work |

### Alignment with Tier 1 contribution areas (from RESEARCH_DOCTRINE.md)

- **Tier 1 #2 — Literature Synthesis & Gap Analysis (score 19/20):** Direct fit. Gap analysis pipeline is exactly the Tier 1 deliverable; the meaningful gaps in §4 are publishable as a synthesis paper if validated with PubMed term-variant checks.
- **Tier 1 #4 — Drug Repurposing Computational Screening (score 18/20):** Three of the top-15 meaningful gaps involve Drug Repurposing (Islet Transplant, Glucokinase, LADA). Pairing the gap finding with an OpenTargets/DrugBank screen would create a Bronze→Silver evidence upgrade.
- **Tier 1 #6 — Epidemiological Data Analysis (score 17/20):** Five of the top-15 meaningful gaps involve Health Equity (Beta Cell Regen, Islet Transplant, Treg/CAR-T, Glucokinase, Drug Repurposing). Pulling CDC/GBD disparity data for the highest-impact pair (Beta Cell Regen × Health Equity) would be a tractable first step.

---

## 5. Breaking News (web search, last ~7 days)

Genuinely significant items only — routine commentary and ADA standards releases skipped.

- **Preclinical T1D reversal — Sweden / mouse study.** Researchers report durable reversal of T1D in mice using combined HSC + islet transplantation to induce mixed chimerism; cited as building on protocol elements already approved in human medicine. Published ~May 5; coverage continuing through May 9. *Evidence level: preclinical (mouse), no human data — note as a Bronze claim if added to tracker.* Aligns with our Tier 1 #2 synthesis work because it bridges Islet Transplant × Autoimmunity T1D × Tolerance Induction.
- **FDA generic dapagliflozin approval (2026-04-07).** First generic Farxiga — relevant to access/equity narratives and to SGLT2 health economics modeling. Already reflected in dapagliflozin PubMed volume spike (5 papers this cycle).
- **FDA approval — Langlara (insulin glargine-aldy biosimilar to Lantus), 2026-04-29.** Adds to insulin biosimilar landscape; secondary impact on cost-effectiveness work.
- **Afrezza pediatric expansion — PDUFA 2026-05-29.** Worth flagging now so we can update the tracker on decision day; if approved, first needle-free pediatric insulin.

No major Phase 3 readouts breaking this week beyond what is already captured in ClinicalTrials.gov result postings.

---

## 6. Recommended Actions

Highest priority first:

1. **Re-run the gap analysis** — `python project1_literature_gap_analysis.py`. Underlying data is 22 days old and external citations would be misleading until refreshed.
2. **Add the teplizumab consensus statement (PMID 42051156) to the paper library** — directly supports our T1D Immunotherapy synthesis and is more citeable than the individual real-world case series.
3. **Update tracker for Sanofi-sponsored teplizumab Phase 3 (NCT07088068)** — sponsorship change from Provention/Sanofi to Sanofi alone has implications for the teplizumab commercial trajectory captured in `teplizumab_sNDA_decision_prep.md`.
4. **Add the two Eli Lilly Baricitinib Phase 3 trials (NCT07222137 at-risk children, NCT07222332 new-onset beta-cell preservation)** to the T1D Immunotherapy & Prevention list in `Diabetes_Research_Tracker.xlsx` — both currently RECRUITING and represent the first Phase 3 baricitinib data we will see for T1D.
5. **Investigate NCT07212179 removal** — the bolus calculator trial was RECRUITING yesterday and is gone from today's snapshot. Could be withdrawn or de-listed; check ClinicalTrials.gov directly before assuming a status change.
6. **Schedule a Beta Cell Regen × Health Equity scoping search** — the gap is at the top of the ranked list and aligns with two Tier 1 areas (#2 Literature Synthesis and #6 Epidemiological Data Analysis). Even a small bibliometric synthesis here would convert a Bronze gap claim to Silver.
7. **Add a tracker entry for the Sweden mixed-chimerism mouse study** — preclinical, Bronze evidence, but it is a natural follow-up node for our Islet Transplant × Autoimmunity T1D dossier.
8. **Note the orforglipron Phase 3 results (NCT05971940) posted 2026-04-22** — verify whether the new PubMed methodology-critique paper (PMID 41984238) raises issues that should be reconciled with the registry results.

No write actions taken — this run is review-only per the task spec.

---

## 7. Validation Notes (per Research Doctrine)

- Trial diff counts (1 new / 1 removed / 1 status change) are reproducible from the May 11 and May 12 JSON snapshots — **SILVER**.
- PubMed cross-domain identification uses `paper.domains` as recorded by the alert script — **SILVER** for membership, **BRONZE** for "highest priority" judgments.
- Gap rankings are reproduced from `literature_gap_data.json` without modification — **BRONZE** until reanalysis confirms no terminology drift.
- Breaking-news items are single-source (web search summaries) — **BRONZE**; do not propagate into tracker as findings without primary-source confirmation.
- No claims here have been independently verified against systematic-review databases (Cochrane, PROSPERO).

---

*Generated automatically by diabetes-hub-monitor — no source files were modified.*
